ATP1A3 and glioblastoma: The current research indicated for the first time that ATP1A3 might exert an important effect on the anti‐cancer activity and chemosensitizing effect of CS‐6, and CS‐6 could be a potent sensitizer of TMZ chemotherapy in GBM via regulating the ATP1A3‐AQP4 signalling pathway.